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Abstract 
5-fluorouracil (5-FU) was isolated as an inhibitor of thymidylate synthase, which is important 
for DNA synthesis. The drug was later found to also affect the conserved 3’-5’ 
exoribonuclease EXOSC10/Rrp6, a catalytic subunit of the RNA exosome that degrades and 
processes protein-coding and non-coding transcripts. Work on 5-FU’s cytotoxicity has been 
focused on mRNAs and non-coding transcripts such as rRNAs, tRNAs and snoRNAs. 
However, the effect of 5-FU on long non-coding RNAs (lncRNAs), which include regulatory 
transcripts important for cell growth and differentiation, is poorly understood. RNA profiling 
of synchronized 5-FU treated yeast cells and protein assays reveal that the drug specifically 
inhibits a set of cell cycle regulated genes involved in mitotic division, by decreasing levels 
of the paralogous Swi5 and Ace2 transcriptional activators. We also observe widespread 
accumulation of different lncRNA types in treated cells, which are typically present at high 
levels in a strain lacking EXOSC10/Rrp6. 5-FU responsive lncRNAs include potential 
regulatory antisense transcripts that form double-stranded RNAs (dsRNAs) with overlapping 
sense mRNAs. Some of these transcripts encode proteins important for cell growth and 
division, such as the transcription factor Ace2, and the RNA exosome subunit 
EXOSC6/Mtr3. In addition to revealing a transcriptional effect of 5-FU action via DNA 
binding regulators involved in cell cycle progression, our results have implications for the 
function of putative regulatory lncRNAs in 5-FU mediated cytotoxicity. The data raise the 
intriguing possibility that the drug deregulates lncRNAs/dsRNAs involved in controlling 
eukaryotic cell division, thereby highlighting a new class of promising therapeutical targets.     
 
 
Key words: 5-fluorouracil, transcription factor, SWI5, ACE2, AMN1, Mitotic Exit Network, 
long non-coding RNAs, antisense RNA, double stranded RNA, chemotherapy, yeast 
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Introduction 
In spite of substantial progress made over the past couple of decades, effective 
chemotherapeutical treatment of most somatic cancers remains a challenge. Within a large 
variety of anti-cancer drugs available, agents that inhibit DNA replication and repair are 
among the oldest and most widely used compounds in therapies of many solid tumors. One of 
the best-studies examples, 5-fluorouracil (5-FU), was initially designed in 1957 to interfere 
with pyrimidine biosynthesis. Later work confirmed its ability to inhibit a key enzyme in this 
pathway, thymidylate synthase, and to interfere with the formation of ribosomal RNA [1, 2, 
3]. Subsequently, 5-FU was proposed to also act through an RNA pathway [4, 5]. The 
mechanism of action involves incorporation of fluorinated uracil into transcripts, which 
converts them into poor substrates for the conserved 3’-5’ exoribonuclease EXOSC10/Rrp6 
[6, 7, 8]. EXOSC10/Rrp6 is involved in global RNA processing and degradation either 
independently of or in association with the RNA exosome, which is a multi-subunit complex 
conserved from yeast to human [9, 10].  
Saccharomyces cerevisiae is a versatile model organism that has been used extensively to 
study mitotic cell growth and division in the presence of anti-proliferative compounds such as 
5-FU [11, 12, 13]. While both DNA- and RNA based mechanisms have been invoked for the 
drug’s effects in cancer cells, it is noteworthy that 5-FU toxicity in S. cerevisiae appears to be 
mostly due to altered RNA processing [5, 13]. This marks yeast out as a useful system to 
study the global transcriptional response to 5-FU. Yeast RRP6, although not annotated as an 
essential gene, is important for normal cell growth and differentiation in various strain 
backgrounds [14, 15, 16, 17]. Its human ortholog EXOSC10 was initially thought to be non-
essential [18], but more recent work demonstrated its critical role for somatic and germ cell 
division in mouse and human [19, 20, 21].  
A large fraction of EXOSC10/Rrp6’s substrates are lncRNAs that are broadly defined as 
transcripts with little or no coding potential. In yeast, this class of RNAs includes cryptic 
unstable transcripts (CUTs) and meiotic unannotated transcripts (MUTs) that accumulate to 
peak levels in a vegetatively growing rrp6 mutant and sporulating wild type cells [16, 22]. 
Two other major types of lncRNAs are Xrn1-sensitive unstable transcripts (XUTs), and 
stable unannotated transcripts (SUTs) [23, 24]. The roles of most lncRNAs are unknown. 
However, a growing body of evidence indicates that many of them are not a dispensable 
byproduct of bi-directional transcription, but regulate gene expression via promoter 
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interference, and sense/antisense (s/a) interference of transcription in both fission- and 
budding yeast [25, 26, 27, 28, 29, 30, 31].  
Regulatory lncRNAs are known to play important roles also in higher eukaryotes, notably 
during mammalian cell growth and differentiation [32]. Specifically, it was shown that a 
dsRNA molecule formed by s/a lncRNAs has important functions in the human cell cycle 
[33]. Such interactions between transcripts are likely not an isolated phenomenon, since 
recent genome-wide profiling methods revealed an unexpectedly complex RNA interactome 
in mammals, which includes numerous antisense lncRNAs [34, 35, 36]. lncRNAs are not 
only interesting from a biological standpoint, they currently also receive much attention as 
drivers of cancer progression [37, 38]. Interestingly, 5-FU induces genes in the interferon 
pathway, and dsRNAs formed by retrotransposons mediate an interferon response in cancer 
cells, when DNA methylation is inhibited [39, 40]. It is, however, unknown if dsRNAs that 
originate from s/a transcript pairs are also able to trigger an immune response to cancer.  
Given that EXOSC10/Rrp6 targets lncRNAs in dividing cells, it is conceivable that 
exoribonuclease-dependent 5-FU toxicity is in part mediated by its ability to alter the stability 
of potential regulatory lncRNAs. To test this idea, we have carried out a genome-wide RNA 
profiling analysis of 5-FU treated versus untreated diploid wild type cells and rrp6 mutant 
control cells synchronously undergoing a mitotic cell cycle. Our study has revealed protein-
coding and non-coding transcripts that show altered levels in 5-FU treated cells and rrp6 
mutant cells. Somewhat unexpectedly, we identified the paralogous transcriptional regulators 
Swi5 and Ace2 as 5-FU targets. These activators are important for the mitotic exit network, a 
group of genes that orchestrates cell cycle progression and cell separation. The analysis also 
identified 5-FU responsive non-coding RNAs, including antisense transcripts that form in 
vivo dsRNAs with sense mRNAs involved cell cycle control. Our results therefore reveal an 
indirect transcriptional effect of 5-FU, and they highlight lncRNAs in general, and antisense 
transcripts that form dsRNAs with overlapping mRNAs in particular, as potential mediators 
of the drug’s RNA-dependent effects on cell division.  
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Results 
Experimental rationale and design 
The major aim of our study was to analyse the effect of 5-FU treatment as compared to RRP6 
deletion on mRNA and lncRNA levels in diploid yeast cells undergoing rapid mitotic growth. 
Since 5-FU down-regulates Rrp6’s activity via substrate inhibition, we expected the drug to 
increase the enzyme’s target transcript levels. Although RNA profiling studies of the mitotic 
cell cycle are typically carried out in haploid cells, we preferred using a diploid strain to 
ensure that the data are comparable to our earlier work on lncRNA and protein expression 
during cell growth and differentiation [16, 41]. Consequently, haploid cell synchronization 
protocols based on pheromone arrest were not suitable. We also sought to avoid temperature 
sensitive mutant alleles of essential cell division cycle genes, since they may have unintended 
effects on 5-FU’s activity, and rrp6 mutant cells (referred to as rrp6Δ) fail to grow at 37ºC. 
We therefore arrested wild type cells in G1 by starvation [42], which is a naturally occurring 
process, before releasing them into fresh rich medium (YPD) in the presence and absence of 
20μg/ml 5-FU (Fig 1). As a control for lncRNA accumulation, rrp6Δ cells were arrested and 
released into rich medium. The strains were sampled at 40 and 100 minutes, which are two 
time points broadly corresponding to G1/S and the onset of G2/M-phases as determined by 
monitoring DNA replication. We note that synchronizing cells enhances fluctuating RNA 
levels, which might be masked in samples from asynchronous logarithmically growing cells. 
We cannot, however, study bona fide cell cycle regulation of coding and non-coding 
transcripts in the presence and absence of 5-FU, because the experiment does not cover at 
least two complete mitotic cycles after nutrient deprivation.  
 
5-FU treatment of diploid yeast cells 
To optimize 5-FU treatment in our diploid JHY222 strain we assayed growth at different 
concentrations and found that 20μg/ml closely mimics the growth phenotype of rrp6Δ cells at 
30ºC. We also confirmed previous findings that cells lacking RRP6 are hyper-sensitive to 5-
FU and that growth at 37ºC exacerbates the drug’s toxic effect (Fig 2A) [5, 11, 12, 43].  
We subsequently monitored progression through G1 and S-phase by FACS analysis of cells 
sampled every 20 minutes until three hours after release into fresh medium. The data 
indicated that most cells had not initiated a new round of mitosis 40 minutes (representing 
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G1/S) into the experiment, and that approximately 50% of the cells had undergone DNA 
replication by 100 minutes (representing G2/M). 5-FU treated wild type cells and the rrp6Δ 
control show a moderate delay at the 100-minute time point and, as expected, a substantial 
delay at 180 minutes (Fig 2B) [11].  
 
The RNA expression landscape of 5-FU treated diploid cells 
We first compared the global RNA signal levels between the samples using a scatter plot 
matrix. This analysis revealed, as expected, a strong effect of RRP6’s deletion, and a similar 
albeit much weaker effect of 5-FU on global RNA levels (S1A Fig). A more specific analysis 
of the transcriptional response shown in density graphs and box plots revealed that CUT 
levels showed the strongest increase in the absence of Rrp6, and in wild type cells treated 
with 5-FU, while mRNA expression levels showed the smallest increase. For SUTs, XUTs 
and MUTs we observed an intermediate response (S1B Fig). These results are consistent with 
CUTs being a major target of Rrp6, and 5-FU inhibiting the enzyme via substrate inhibition 
[6, 22].       
We next identified genes for which we observed fluctuating levels across the sample set. 
Given the experimental setup, we expected a transcriptional response related to cells 
progressing from G1/S toward G2/M together with the effects due to lacking Rrp6 activity 
and 5-FU treatment. We first identifie  9786 RNAs (including 5596 mRNAs, 400 dubious 
open reading frames (ORFs) and 3651 lncRNAs) that showed an expression value given in 
counts per million (CPM) >1 in at least four out of 12 samples. Subsequently, we employed 
TMM normalization and a statistical test implemented in EdgeR corrected for multiple 
testing (adjusted p-value <0.05) to filter 5697 significantly differentially expressed RNAs 
(see methods). They include 2617 validated mRNAs, 248 transcripts encoded by dubious 
ORFs, and 2778 RNAs annotated as non-coding RNAs that fall into five classes (CUTs, 
SUTs, rsSUTs, MUTs and XUTs). This multi-step procedure was used to decrease the false-
positive rate due to very low expression signals (see methods). Finally, we empirically 
grouped the mRNAs into five clusters using the supervised k-means algorithm. Clusters C1 
and C2 contain genes that respond to 5-FU and/or rrp6Δ. C3 contains genes for which we 
observe decreased levels in rrp6Δ and 5-FU. C4 and C5 contain mRNAs that tend to peak at 
the G1/S or G2/M time points, respectively, in all three conditions (Fig 3B). The latter two 
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patterns are exemplified by the G1 cyclin CLN2 (C4) and the B-type cyclin CLB2 (C5) (Fig 
3C; S2 Table).  
To further analyse the functional relevance of our clustered target transcripts, we identified 
significantly enriched Gene Ontology (GO) terms from the biological process ontology (S2 
Figure, S3 Table) and we manually searched the clusters for genes related to cell growth, 
division and stress response [44]. C1 contained genes important for the mitotic cell cycle and 
cell division such as a cyclin (PCL9) but showed no statistically significant enrichment of 
these biological processes. We found that C2, for which we also detected no GO term 
enrichment, contained genes involved in processes relevant for 5-FU and the known 
phenotype of rrp6Δ . They include DNA repair (HIM1, POL2, SSL2), DNA replication 
(ORC5, PSF1, SLD5), regulation of gene expression relevant for stress response and 
ribosomal RNA synthesis (ABF1, HCM1, MOT3, RGT1, RRN3, RRN7), and cell cycle 
progression (BUB2, CDC34). We also observed genes important for meiosis (MEI4, RED1) 
and spore formation (SPO19, SPO73, SSP2) in C2. This is unsurprising, since our 
experimental protocol involved arresting diploid cells in G1 via starvation, which primes 
them for entry into the meiotic differentiation pathway (the full execution of which requires, 
however, the simultaneous absence of a fermentable carbon source and nitrogen; see 
methods) [45].  
Cluster C3 contains genes that fail to be upregulated to normal levels in rrp6Δ and in 5-FU 
treated cells that progress through S-phase toward G2/M. Most of these genes are involved in 
metabolic processes, notably metabolism (ENO1, GPM1, TDH2) and transport (OPT1, SIT1). 
C3 also contains genes important for the cell cycle (AMN1, CTS1, DSE1, DSE2, DSE3, 
DSE4, EGT2). The reasons for this rrp6Δ-dominant effect are unclear but they are likely 
related to the complex nature of the mutant phenotype [46, 47] (S2A Fig).    
Cluster C4 identifies genes that show a broadly similar pattern of decreased expression in the 
100-minute samples in all three conditions. Enriched processes include DNA-dependent 
DNA replication (CDC9, CDC45, RAD27, RFA1, RFA2, RFA3, SIM1) and DNA damage 
stimulus (MSH6, RTT107). We note, however, that some DNA repair genes are induced by 5-
FU. Such cases include enzymes important for nucleotide excision repair (RAD4), double 
strand break repair (PRI2), recombination (SMC6), mismatch repair (PMS1), and DNA-
damage induced transcription (DUN1). These patterns reflect 5-FU’s impact on cell cycle 
progression and DNA integrity [48, 49] (S2B Fig).  
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In Cluster C5, where we observe consistent up-regulation in the entire sample set, a range of 
genes involved in amino acid biosynthesis pathways (ARO3, HOM2, ILV6, MET6, MET17, 
MMP1) appears to be unaffected by RRP6 gene deletion and drug treatment. It is noteworthy 
that this cluster also contains cell cycle regulators that are not perturbed at the level of mRNA 
expression (CLB1, CLB2, SPO12). Although this group is not significantly enriched, it 
appears that neither 5-FU nor rrp6Δ prevent cell cycle regulated genes in general from being 
expressed in our experimental setup (S2C Fig).  
 
5-FU affects the mitotic exit network via the activator Swi5  
Cluster C3 contained the Antagonist of the Mitotic Exit Network (AMN1), which is involved 
in mitotic checkpoints and chromosome stability. The gene is down-regulated by 5-FU and 
(albeit to a lesser extent) by rrp6Δ at the 100-minute time point [50, 51] (Fig 4A). We 
confirmed the RNA-Sequencing data in an independent experiment using RT-PCR (Fig 4B). 
Furthermore, we observed similar patterns for a cyclin-dependent kinase inhibitor (SIC1) and 
genes involved in daughter cell separation (CTS1, DSE1, DSE3, DSE4, EGT2; Fig 4C). The 
distinctive expression pattern of these genes likely explains why they were clustered apart 
from most other cell cycle regulated genes in C4 and C5 that appeared to be unperturbed at 
the transcriptional level. These findings prompted us to search for more genes important for 
cell separation and cell wall synthesis that showed negative 5-FU/rrp6Δ response patterns. 
We indeed found AIM44 and PIR1 in C5 (Fig 4C). We note that the transcripts shown in Fig. 
4C accumulate to higher levels in rrp6Δ cells than in the wild-type at the 40 minute time 
point. It could be that they are under negative control of Rrp6 during G1/S phase.    
The observed patterns could be explained by mechanisms either involving RNA synthesis 
(gene activation) or RNA degradation (transcript stability). To distinguish between these 
possibilities we interpreted information about published in vivo protein/DNA binding data 
from microarray-based chromatin immunoprecipitation (ChIP-Chip) experiments that are 
online available via the YEASTRACT (www.yeastract.com) database [52]. This confirmed 
that, among others, AMN1, AIM44, DSE1, DSE2, DSE4, EGT2, PCL9, PIR1 and SIC1 are 
likely direct targets of the DNA binding activator Swi5 [53, 54, 55]. We therefore examined 
RNA levels for SWI5 and found that it was expressed at lower levels in 5-FU than untreated 
cells at 100 minutes, while no negative effect was apparent in the rrp6Δ sample (Fig 5A). 
This pattern was confirmed at the protein level. Swi5 protein is undetectable under our 
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experimental conditions in the 40-minute samples, while it accumulates to roughly equivalent 
levels in WT and rrp6Δ cells but not in 5-FU treated WT cells at 100 minutes (Fig 5B). It is 
unclear why we cannot detect Swi5 at the early 40-minute time point but it might be 
degraded in diploid cells undergoing glucose starvation and G1 arrest, perhaps by the 
ubiquitin ligase SCF(Cdc4) that is known to target Swi5 during the cell cycle [56]. Swi5’s 
decrease at the 100-minute timepoint could in part explain the strong negative effect 5-FU 
has on the expression of its target genes. An additional contribution could be made by partial 
cytoplasmic retention of Swi5 in treated cells, bearing in mind that the protein is in part 
regulated via subcellular localisation [57].  
 
5-FU treatment affects different classes of lncRNAs  
Given that 5-FU-treatment leads to the production of modified transcripts, which are 
inefficient substrates for  Rrp6’s ribonucleolytic activity we hypothesized that the drug might 
stabilize potential regulatory lncRNAs [6, 7]. At least some of these RNAs, notably antisense 
transcripts that form dsRNAs with their overlapping sense mRNAs or with other lncRNAs, 
possess regulatory functions or have been associated with altered protein levels [41, 58]. 
To gain insight into the RNA profile of diploid cells treated with 5-FU versus rrp6Δ, we first 
grouped 2778 lncRNAs, including CUTs, SUTs, MUTs and XUTs, into five clusters broadly 
representing a positive 5-FU/rrp6Δ response (C1-C2), a negative 5-FU/rrp6Δ response (C3), 
peak expression in G1/S (C4) and peak expression in G2/M (C5) (Fig 6). These patterns were 
reminiscent of what we obtained with mRNAs. The overall response is comparable in 5-FU 
and rrp6Δ samples but the lncRNAs accumulate to much higher levels in the gene deletion 
mutant. This was to be expected since the deletion strain entirely lacks Rrp6 activity, while 
the enzyme might only be partially affected in the 5-FU treated wild type strain.  
Given the regulatory potential of these non-coding RNAs, we next focused on the sub-class 
of 804 5-FU/rrp6Δ responsive antisense lncRNAs that overlapped sense mRNAs (Figure 7A 
and S4 Table; note that the table contains 825 entries because of multiple overlap cases). GO 
term analysis revealed no significant enrichment, but we observed genes involved in meiosis 
(MEI4, PCH2, RED1, ZIP2), sporulation (ADY4, SPO22, SPO77) and, notably, cell growth 
(cell wall organization; e.g. CWP1, EXG2) (S4 Table). We next asked if these s/a transcript 
pairs form dsRNAs in vivo. To this end, we interpreted data from a published dsRNA 
profiling experiment using a haploid wild type strain and a mutant strain lacking the 5’-3’-
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exoribonuclease Xrn1 (meant to amplify the signal by stabilizing antisense transcripts) that 
ectopically express fungal Dicer and Argonaute orthologs from N. castellii. These enzymes 
cleave dsRNAs and the breakdown products are detected by small RNA-Sequencing [58]. 
Using these dsRNA profiling data, we observed clear dsRNA signals for several meiotic 
genes and, importantly, the cell growth factors CWP1 and EXG2 (S3 Figure).  
The group of s/a loci also contained a class of genes involved in response to chemicals, such 
as MNL1/SUT597 that is relevant for 5-FU treatment. MNL1 is potentially interesting 
because it is conserved from yeast to mammals (Mnl1/EDEM1)and plays a role in resistance 
to chemicals via the unfolded protein response pathway. Its antisense RNA SUT597 is 
upregulated in the presence of 5-FU and the absence of Rrp6 as shown both by RNA-
Sequencing and an RT-PCR assay (Figure 7B-D). As expected, a stable dsRNA is formed by 
MNL1/SUT597 s/a transcripts (Figure 7E). CUT158/MTR3 is also interesting because this 
conserved gene (EXOSC6 in human) is involved in RNA exosome-dependent transcript 
processing and degradation. CUT158 accumulates in 5-FU treated and rrp6 mutant cells as 
monitored by RNA-Sequencing and RT-PCR assay and forms a dsRNA that covers almost 
the entire MTR3 coding sequence (S4 Fig A-D).   
Intriguingly, the group of s/a loci includes the SWI5 paralog ACE2, and its overlapping 
antisense lncRNAs CUT259 and SUT2107 that show opposing peak expression patterns both 
in RNA-Sequencing and stranded RT-PCR experiments (Fig 8A-C). We observed that ACE2 
mRNA is moderately down-regulated by 5-FU but not rrp6Δ (Fig 8A-B). When we measured 
Ace2 levels by Western blot, we found that the protein failed to accumulate to wild type 
levels at the 100-minute time point in both treated and mutant cells; this effect became 
weaker at a later time point at 160 minutes (Fig 8D). This finding raised the question why 
Ace2 did not accumulate to normal levels in 5-FU treated and rrp6Δ cells although mRNA 
levels remain almost the same. It is possible that the mechanism, which down-regulates the 
protein in both conditions involves ACE2/SUT2107 dsRNA formation, which occurs in 
haploid cells undergoing growth in rich medium (Fig 8E) [58]. We therefore assayed 
ACE2/SUT2107 transcript pairs in our sample set from diploid cells using an 
immunoprecipitation assay based on the dsRNA-specific J2 antibody and RT-PCR [59]. We 
detected weak signals in untreated and treated cells, and a stronger signal in the rrp6Δ 
background that was consistent with the increase of sense and antisense RNA levels in this 
strain (Fig 8F). Finally, we confirmed that the J2 assay is suitable for detecting fluctuating 
dsRNA signals due to variable transcript levels by monitoring GAP1/SUT1912 that are very 
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weakly expressed in fermenting mitotic cells (YPD) and induced in meiotic cells (cultured in 
sporulation medium SPII; S5 Fig A-C; the complete dataset will be published elsewhere).  
We conclude that antisense SUT2107 levels are increased moderately by 5-FU and strongly 
by rrp6Δ, thereby drawing ACE2 sense mRNA into a dsRNA complex. The ACE2/SUT2107 
double-stranded form covers almost the entire coding region of ACE2, and is associated with 
diminished Ace2 protein levels in 5-FU and rrp6Δ samples. This result complements our data 
on Swi5, because Ace2 is known to co-activate certain Swi5-dependent cell cycle genes, and 
other genes important for cell division, such as CTS1 ([60] and references therein). Our 
findings indicate that 5-FU negatively affects Swi5 and Ace2 transcription factors that are 
important for normal cell cycle progression via the Antagonist of the Mitotic Exit Network 
(MEN) pathway, and its downstream target genes. The data highlight a transcriptional 
regulatory aspect of 5-FU’s toxicity that implicates important cell cycle regulators, and stable 
lncRNAs/dsRNAs. Finally, the results provide molecular insight into the complex mitotic 
growth phenotype shown by rrp6Δ cells in different strain backgrounds at permissive and 
restrictive temperatures [16, 17, 61].  
 
 
Discussion 
The anti-cancer drug 5-FU is incorporated into RNA and thereby indirectly inhibits the 3’-5’ 
exoribonuclease EXOSC10/Rrp6, which is an evolutionarily conserved protein that processes 
or degrades different types of non-coding RNAs. Since certain long non-coding RNAs have 
been reported to be important for cell growth, development and diseases such as cancer, we 
hypothesized that part of 5-FU’s cytotoxicity might stem from its ability to alter the stability 
of known or putative regulatory lncRNAs. To provide initial evidence for the concept in a 
model system suitable for RNA profiling of cell cycle progression, we analysed the effect of 
5-FU on the transcriptome of synchronized diploid budding yeast wild type versus rrp6 
mutant cells. The latter served as a positive control since cells lacking Rrp6 accumulate 
lncRNAs, and fail to divide normally; that is, while the phenotype is more or less severe at 
the permissive temperature depending on the background, all mutant strains arrest at the 
restrictive temperature of 37ºC.  
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EXOSC10/Rrp6 is important for cell growth and development 
We find that the vast majority of 5-FU/rrp6Δ dependent lncRNAs accumulate to much higher 
levels in the gene deletion mutant than in drug-treated cells, yet JHY222 rrp6Δ cells can 
grow and divide. While this seems to argue against a major effect of deregulated lncRNAs on  
cell division, we underline that JHY222 rrp6Δ cells do show a moderate growth phenotype at 
30ºC, and fully arrest at 37ºC. Moreover, mutant cells in the SK1 background fail to grow 
normally even at the permissive temperature [16, 17]. Finally, Rrp6’s important role in yeast 
is mirrored in mammals by our own results, and other recent reports showing that EXOSC10 
is essential for cell division in mouse and human [19, 20, 21]. 
 
Rrp6 deletion and 5-FU treatment elicit an overlapping and conserved response. 
It was proposed earlier that 5-FU’s toxic effect in yeast is based on DNA and RNA 
dependent mechanisms, but that the RNA pathway was dominant [5, 13]. A tiling array-based 
RNA profiling study of the 5-FU response in the fission yeast S. pombe, in combination with 
genetic analyses, provided additional evidence for 5-FU’s effect on RNA processing; it is 
noteworthy that transcripts encoded by genes conserved between the distantly related 
budding- and fission yeasts, such as SNU66, PRP8 and ESF2, respond to the drug (S6 Fig) 
[62]. Elegant work using pre-mRNA splicing reporter genes demonstrated that mRNA 
processing is impaired in a similar fashion when cells are treated with 5-FU or lack Rrp6, and 
that overexpressing RRP6 reverses the effect of the drug on reporter gene expression [63]. 
Taken together, these data are consistent with the idea that an important, and at least partially 
conserved element of 5-FU’s cytotoxic effect is mediated via altered RNA processing.     
 
5-FU destabilizes transcription factors critical for cell division 
While mRNAs encoded by many cell cycle regulated genes showed the expected fluctuations 
after release into rich growth medium (see clusters C4 and C5 in Fig 3B), we found that some 
of the genes involved specifically in cell cycle progression (AMN1, SIC1, PCL9) and cell 
separation (EGT2 and, among others, the DSE genes) failed to be induced to normal levels. A 
literature and database survey of activators targeting the promoters of protein-coding 5-FU 
target genes identified the paralogous transcriptional activators Swi5 and Ace2 that are 
known to be extensively regulated at the level of protein stability and localisation; reviewed 
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in [64]. Our data point to simultaneous down-regulation of Swi5 and Ace2 as a mechanism 
for 5-FU’s ability to prevent the induction of certain cell cycle regulated genes. We did not 
expect to find that 5-FU affects regulatory proteins, however, the result is consistent with the 
earlier finding that 5-FU decreases the levels of mammalian transcription factors important 
for cell proliferation, such as ATF2, IRF2, and REL [65].   
It is not clear why Swi5 is down-regulated by 5-FU but not rrp6Δ. It could be that the drug 
elicits a combination of effects such as decreased mRNA synthesis and protein instability 
caused by altered activity of cell cycle regulated proteases [56]; for review, see [64].  
 
Do lncRNA-mediated effects contribute to 5-FU’s toxicity?  
The simplest explanation, which has been proposed before, is that modified RNAs are 
suboptimal substrates for Rrp6, and therefore tend to accumulate in 5-FU treated cells [6, 7]. 
This is consistent with our finding that lncRNAs, which increase when cells are exposed to 5-
FU, strongly accumulate in cells lacking Rrp6. However, 5-FU might also up-regulate 
lncRNAs by negatively affecting conserved components of the RNA degradation machinery, 
such as EXOSC10/Rrp6, given that the gene is associated with an overlapping antisense 
lncRNA.    
dsRNAs were proposed to play a major role in the regulation of bacterial gene expression 
[66]. In yeast, dsRNAs formed by s/a transcripts are involved in controlling the stability of 
mRNAs and XUT-type regulatory lncRNAs [58, 67]. In mammals, a dsRNA plays an 
important role during cell cycle progression by binding regulatory proteins [33]. In addition, 
we recently reported evidence that developmental stage-specific formation of dsRNAs is 
negatively correlated with protein levels [41]. We noticed that, in spite of the fact that SWI5 
and ACE2 are paralogs, only the latter is associated with clearly expressed (and annotated) 
antisense lncRNAs (CUT259 and SUT2107). Both of these antisense transcripts accumulate 
in drug-treated and mutant cells and therefore recruit ACE2 sense mRNA into a dsRNA form 
that is stable in vivo. This could prevent the mRNA from being transported into the 
cytoplasm or it could inhibit Ace2 protein translation by hindering the mRNA’s association 
with ribosomes. In this context we note that, contrary to Swi5, Ace2 protein levels are down-
regulated during the initial phases of cell cycle progression by both 5-FU and rrp6Δ, as one 
would expect if accumulating lncRNAs were to be involved.  
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Are yeast 5-FU/Rrp6-targeted lncRNAs relevant for human cancer?  
The function of EXOSC10/Rrp6 as a subunit of the RNA exosome has evolved over time and 
so have its set of substrates or activities [68, 69, 70]. For example, it has been proposed that 
mammalian EXOSC10 may be more efficient at processing structured RNAs than yeast Rrp6 
[71]. These differences notwithstanding, our data highlight the regulatory potential of 5-
FU/Rrp6 responsive lncRNAs/dsRNAs in eukaryotes. This is a promising lead, especially in 
light of recent evidence that human EXOSC10 is an unfavorable prognostic marker for liver 
cancer [72]. 
Our yeast data provide global evidence that lncRNAs of all currently known major types 
accumulate in 5-FU treated cells, including antisense RNAs that form dsRNAs with 
overlapping sense mRNAs. Furthermore, we find again that dsRNAs are associated with 
decreased protein levels (see Fig 8; [41]). Is further experimental work in yeast, such as 
preventing the expression of specific antisense lncRNAs by deleting promoter regions, 
critical? Perhaps not. The evolutionary distance between yeast and human is large, and 
individual lncRNAs are not conserved at the sequence level from yeast to mammals. 
Consequently, a future priority is to identify, and further analyse EXOSC10/Rrp6-dependent 
human lncRNAs that respond to 5-FU using RNA-Sequencing and CRISPR/dCas9 based 
methods [73]. This approach will likely yield useful results, since earlier microarray-based 
work showed that 5-FU alters microRNA and lncRNA expression profiles in cultured breast- 
and colon cancer cells [74, 75, 76]. Critically, genome-wide mammalian RNA interactome 
data are now available [34, 35, 36, 77]. They should prove extremely useful in elaborating 
hypotheses about the roles of mammalian lncRNAs, and the transcripts they form dsRNAs 
with, in the etiology and progression of cancer. 
Recent advances in tumor genomics and personalized medicine have helped conceptualize 
promising new approaches, such as immunotherapy in cancer treatment that complement 
chemotherapies today, and will perhaps replace them in the future [78, 79]. However, gaining 
insight into novel molecular mechanisms underlying the toxicity of 5-FU that has been used 
for decades, will likely continue to be important in the foreseeable future [80]. The yeast 
work reported here provides initial evidence in a simple eukaryotic model organism for roles 
of lncRNAs and dsRNAs in mediating 5-FU’s toxicity. Such a mechanism would open up 
novel therapeutical targets that may help improve the outcome of established anti-cancer 
treatments.  
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Materials and Methods 
Strain backgrounds  
The strains employed for RNA profiling work were JHY222 MATa/α (derived from the 
standard yeast strain S288C) and JHY222 MATa/α rrp6 that were described in [16], Table 1. 
In the JHY222 background, contrary to SK1, deletion of RRP6 is not lethal under laboratory 
conditions, but causes a growth phenotype and impairs meiosis and spore formation [16, 17]. 
 
5-fluorouracil dose optimization 
Cells were cultured in YPD over-night and diluted to 2x106 cells/ml in fresh YPD. 10μl of a 
suspension from serially diluted yeast cells (10-fold to 104-fold) was deposited on standard 
YPD plates containing 20μg/ml 5-FU and cultured for 48 hours at 30ºC or 37ºC. Pictures 
were taken using the GE Imager system (General Electric, USA) at 48h. 
 
Culture conditions and 5-fluorouracil treatment 
Wild type and rrp6 mutant cells from fresh plates were inoculated in standard growth 
medium (YPD), and cultured over night at 30ºC in a rotatory shaker (New Brunswick) for 19 
hours. The cells were spun down and washed with pre-warmed water twice before they were 
re-inoculated into parallel cultures with growth medium (wild type and rrp6Δ) and YPD 
containing 20μg/ml 5-FU (wild type) at a concentration of 2x106 cells/ml. Samples were 
harvested immediately after inoculation and then every 20 minutes until three hours, spun 
down, frozen in liquid nitrogen and stored at -80ºC for further analysis. An aliquot was fixed 
in ethanol and used to monitor DNA synthesis.  
 
Fluorescence activated cell sorting (FACS) analysis 
To monitor the progression of diploid cells through mitotic S-phase, 107 cells were 
resuspended, fixed with 70% ethanol and sonicated using a Branson Sonifier 250 for 10 
seconds at 20% power, before they were analysed as described in [16].     
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Genome-wide strand-specific RNA-Sequencing library preparation 
For each condition, we isolated total RNA from biological duplicates using the hot phenol 
method as described [81]. Ribosomal RNA was removed using the RiboMinus Eukaryote 
System v2 kit (ThermoFisher, France). We next prepared strand-specific RNA-Sequencing 
libraries starting from 125 ng of rRNA-depleted RNA using the TruSeq Stranded Total RNA 
Sample Preparation kit (Illumina, USA), as described [58]. Before carrying out stranded 
RNA-Sequencing, we controlled total RNA and cDNA quality using the RNA 6000 Pico kit, 
and High Sensitivity DNA chips, respectively, and a BioAnalyzer 2100 (Agilent, France).  
 
RNA-Sequencing data production and processing  
We employed a HiSeq2500 sequencer (Illumina) to carry out paired-end sequencing of the 
libraries (2 x 50 nucleotides). Reads were mapped onto the S. cerevisiae S288C reference 
genome using TopHat version 2.0.6 [82]. Parameters were set at a tolerance of three 
mismatches and a maximum intron size of 2 kb [30, 58]. Further bioinformatics analyses 
were carried out with uniquely mapped reads. Tag densities for genes, dubious ORFs, 
sn(o)RNAs, tRNAs and several classes of lncRNAs (including CUTs, SUTs, rsSUTs, XUTs 
and MUTs) were obtained after normalization over the total number of reads that uniquely 
mapped to ORFs. Mapping statistics are summarized in S1 Table.   
 
RNA profiling data analysis 
To identify differentially expressed transcripts, we focused on transcripts with >1 count per 
million (CPM) in at least four out of 12 experiments. Such a filtering step is recommended 
for microarray and RNA-Sequencing based profiling experiments, since genes with very low 
counts across libraries do not provide robust evidence for differential expression [83, 84]. 
The library size was recomputed after this filtering step and counts were normalized using the 
TMM approach [85], and the differential analysis was performed with EdgeR [86, 87]. The 
tested contrasts were either focused on the condition and the time point. The Benjamini and 
Hochberg correction for multiple testing was applied and transcripts with a corrected p-value 
<0.05 were selected as being significantly differentially expressed [88]. The analysis was 
performed using the EdgeR Bioconductor package [89]. 
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Clustering and Gene Ontology Term enrichment 
Different strategies were employed to determine the optimal clustering method and its 
parameters. We tested from k=4 to k=20 using k-means [86], and Partitioning Around 
Medoids (PAM) [87]. We generated silhouette plots of each step to assess the clustering 
methods’ efficiency. This, together with visual inspection of the heatmaps enabled us to 
identify k-means, k=5 as the best approach. Gene Ontology (GO) Biological Process term 
enrichment was computed using GoTermFinder whereby GO terms with adjusted p-values 
below 0.01 were considered as significant [90]. For clusters with enriched GO terms, 
ReviGO was then used to cluster the significant GO terms based on their semantic similarity 
(default parameters) [91].  
 
Raw- and processed data availability 
Raw data files were uploaded to the NCBI’s GeneOmnibus (GEO) repository and are 
available under the accession number GSE77511 [92]. The RNA-Sequencing data for all 
replicates and averaged duplicates are also conveniently accessible online in a searchable 
viewer at http://vm-gb.curie.fr/mprimig/5FU.     
 
Genome-wide detection of dsRNAs 
Genome-wide data on dsRNA formation in haploid wild type and xrn1 mutant cells were 
previously published [58]. The RNA-Sequencing data are available online at http://vm-
gb.curie.fr/mw2/small_RNA-seq/.  
 
Immunological detection of dsRNA 
An RNA immunoprecipitation (RIP) assay was performed using the dsRNA-specific J2 
antibody [59]. RNA was extracted with cold phenol. 35μg RNA was incubated with 3.5μg 
dsRNA-specific J2 antibody (Scicons, France) at 4ºC overnight. Dynabeads were prepared 
according to the manufacturer’s instructions and incubated with the antibody-RNA mixture 
on a rotator at 4ºC for 2h. RNA was washed, eluted and treated with DNaseI (Ambion, 
France). Finally, precipitated RNA was reverse transcribed using the High Capacity cDNA 
Reverse Transcription kit (ThermoScientific, USA)  and amplified using Taq Polymerase 
(Qiagen, France) at 60ºC for 30 cycles using the primer pair for ACE2 (Table 2).  
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RT-PCR assays 
Strand-specific RT-PCR assays were carried out using the SuperScript II kit 
(ThermoScientific, USA). 2μg of  RNA was treated with DNaseI (Ambion, USA), and 
reverse transcribed with reverse primers (shown in Table 2), in the presence of Actinomycin 
D to prevent second strand synthesis. After reverse transcription, the samples were treated 
with RNase H (TEBU BIO, France) to remove the RNA template. cDNA was PCR amplified 
using Taq polymerase (Qiagen, USA) at 60 ºC for 28 cycles. RT-PCR products were 
separated on 2% agarose gels and photographed using the Gel-doc XRS image system (Bio-
Rad, USA). Primers used for RT-PCR were designed using NCBI Primer-Blast program. 
Standard RT-PCR assays were performed as published [93]. Briefly, RNA was extracted 
using the hot phenol method, followed by DNase I treatment with TURBO DNA-free Kit 
(Ambion, USA). RT-PCR reactions were carried out using 2 μg of RNA reverse transcribed 
with Reverse Transcriptase (High Capacity cDNA Reverse Transcription kit; Life 
Technologies, USA) and amplified using Taq Polymerase (Qiagen, France) at 60ºC for 28 
cycles. RT-PCR products were separated on 2% agarose gels and photographed using the 
Gel-doc XRS image system (Bio-Rad, USA). Primers used for RT-PCR were designed using 
Primer3 (simgene.com/Primer3; Table 2).  
 
Western blotting 
Protein extracts were prepared from samples of cells cultured in rich medium (YPD), pre-
sporulation medium (YPA), and sporulation medium (SPII) as described in [94]. 20μg of 
total protein extract was separated by SDS-PAGE gel electrophoresis (Bio-Rad, USA) and 
transferred to ImmobilonPSQ membranes (Millipore, France) using an electro-blotter 
(TE77X; Hoefer, USA) set at 50mA for 2.5h. The membrane was blocked with 5% milk 
powder at room temperature for 1h, incubated with anti-Swi5 and anti-Ace2 antibodies 
(1:1000) overnight at 4°C. A secondary anti-rabbit antibody (1:10000) was incubated at room 
temperature for 1h. An anti-Pgk1 antibody (1:10000) was incubated at room temperature for 
1h before the signals were revealed using an anti-mouse secondary antibody (1:10000) 
incubated at room temperature for 1h. Protein signals were revealed using the ECL-Plus 
Chemiluminescence kit (GE Healthcare, USA) and the ChemiDoc XRS system (Bio-Rad, 
USA). Band intensities were quantified with the ImageQuant TL 7.0 software at standard 
settings (GE Healthcare, USA). 
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Figure legends 
 
Fig 1. Experimental approach. A flow chart shows the color coded wild type (green) and 
mutant (red) strains that were employed in the RNA profiling experiment including cell 
culturing, data production and analysis and validation steps.  
   
Fig 2. Monitoring cell growth and DNA replication. (A) Images show the outcome of a 
plate growth assay after 48 hours at the temperatures indicated at the bottom on rich medium 
(YPD) at permissive (30ºC) and restrictive temperatures (37ºC) for wild type (WT in green) 
and mutant (rrp6 in red) cells in the strain indicated to the left. The drug concentration is 
given to the right. Grey triangles at the top indicate increasing dilution of the cell suspension. 
(B) The output of a FACS analysis is given. The time points are given in minutes and are 
shown to the left; the samples that were further analysed are shown in red. Color-coded 
untreated wild type (WT in green), treated wild type (WT 20μg/ml 5-FU in purple) and 
mutant (rrp6 in red) cell samples are shown at the top. DNA content and strain background 
are given at the bottom and to the right, respectively.  
  
Fig 3. RNA-Sequencing analysis strategy and output. (A) A flow chart outlines the RNA-
Seq data analysis strategy. (B) A color-coded heatmap (red is high and blue is low) shows the 
expression patterns for protein-coding RNAs (mRNAs) grouped into five clusters (C1-C5) 
given to the left for sample duplicates from wild type (WT), treated wild type (5-FU) and 
mutant (rrp6Δ) cells as shown at the top. The time points are indicated in minutes. The 
clusters are biologically classified into genes that respond to treatment and gene deletion (5-
FU/rrp6Δ), gene deletion (rrp6Δ) and cell cycle peaks (G1/S and G2/M). A color scale is 
shown at the bottom. (C) Color-coded histograms are shown for G1/S and G2/M marker 
genes as given at the top. The sequence (x-axis) is plotted against expression signals (y-axis) 
for wild type cells (WT40, WT100, shades of green), treated cells (5-FU40, 50-FU100, 
shades of blue) and mutant cells (rrp6Δ40, rrp6Δ100, shades of red) at 40 and 100 minutes 
after release into fresh medium. The data range set in IGV is indicated.   
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Fig 4. Expression data for cell cycle genes. (A) A histogram of RNA-Sequencing data is 
shown for AMN1 like in Fig 3C. (B) An RT-PCR assay is shown (top) and band intensities 
are quantified (bottom) for AMN1. ACT1 was used as a control. Samples in lanes 1-6 are 
indicated at the top and bottom. The strain background is given to the left. (C) Expression 
data are shown as histograms for selected cell cycle genes as indicated at the top, like in Fig 
3C.  
  
Fig 5. SWI5 RNA and protein analysis. (A) A histogram is shown for SWI5 like in Fig 3C. 
(B) A Western blot assay is shown for Swi5 in strain backgrounds indicated at the bottom. 
Pgk1 was used as a loading control. Non-specific bands are indicated with an asterisk to the 
right. Lanes 1 and 2 contain samples from wild type (WT) and swi5 deletion (swi5Δ) strains. 
Lanes 3-8 contain wild type cells (WT40min, WT100min), treated cells (5-FU40min, 50-
FU100min) and mutant cells (rrp6Δ40min, rrp6Δ100min) 40 and 100 minutes after release 
into fresh medium.  
 
Fig 6. RNA profiling of lncRNAs. A color coded heatmap is shown for lncRNAs like in Fig 
3B. Clusters (C1-C5) and response classes are given to the left and right. Sample duplicates 
are indicated at the top. A color scale is shown at the bottom. 
 
Fig 7. Expression data for antisense lncRNAs. (A) A color coded heatmap for antisense 
lncRNAs (AS lncRNAs) is shown as in Fig. 6. (B) Color-coded genomic heatmaps are shown 
for mRNAs in blue, and lncRNAs in light grey (SUTs), red (XUTs) and green (CUTs). 
Chromosome numbers and genome coordinates are given in the middle. Red boxes delineate 
selected lncRNAs. Wild type (WT), treated (WT 5-FU) and mutant (rrp6) samples, and the 
time points in minutes are shown to the right. Top (+) and bottom (-) DNA strands and a 
scale are given to the right. Images were generated using VING software [95]. (C) A bar 
diagram shows quantified RNA-Sequencing expression signals for SUT597. The expression 
signal (y-axis) is plotted against the samples (x-axis) as shown at the bottom. Time points are 
given for wild type (WT), drug-treated (5-FU) and mutant (rrp6) samples. Data are presented 
as mean values +/- SEM (calculated from two biological replicates used in the RNA-
Sequencing analysis). (D) An RT-PCR assay is shown for antisense lncRNAs and 
overlapping sense mRNAs as indicated to the right. Wild type (WT), treated (WT 5-FU) and 
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mutant (rrp6) samples, and the time points in minutes are given at the top. ACT1 was used as 
a loading control. (E) A color-coded graph plots the 19-23 base small RNA read densities 
(tag/nucleotide, y-axis) against top (+) and bottom (-) strands of the genome (y-axis). Protein-
coding and non-coding genes are represented by arrows for which the color code is like in 
panel B. Data are shown in black for a wild type strain (WT, dotted line), and a strain 
expressing Dicer/Argonaute (RNAi), and in red for a mutant strain (xrn1, dotted line), and a 
mutant strain expressing Dicer/Argonaute (xrn1 RNAi). Chromosome numbers and genome 
coordinates and are given at the top and bottom, respectively. The images were generated 
using the VING software and previously published small RNA-Sequencing data [58, 95]. To 
view a larger region covering the loci and a graphical representation of the signals showing 
wild type and engineered RNAi strain separately, see http://vm-gb.curie.fr/mw2/small_RNA-
seq/. 
 
Fig 8. Sense/antisense RNA and protein expression data for ACE2/SUT2107/CUT259. 
(A) A genomic expression heatmap for the region containing ACE2/SUT2107/CUT259 is 
shown like in Fig 7B. (B) A bar diagram shows qu ntified RNA-Sequencing expression 
signals for ACE2, CUT259 and SUT2107 as in Fig 7D. (C) An RT-PCR assay is shown for 
ACE2 and SUT2107 like in Fig 7E. A non-specific band in marked with an asterisk. ACT1 
was used as a loading control. (D) A Western blot assay is shown for Ace2 like in Fig 5B. A 
non-specific band is marked with an asterisk. Pgk1 was used as a loading control. Samples 
are given at the bottom and at the top. Band intensities are shown in a histogram where 
samples (x-axis) are plotted against relative intensity units (y-axis). (E) A color-coded graph 
plots the 19-23 base small RNA read densities (tag/nucleotide, y-axis) against top (+) and 
bottom (-) strands of the genome (y-axis) like in Fig 7 F. (F) An immunoprecipitation (IP) 
assay is shown using the dsRNA specific J2 antibody for the s/a pair given at the bottom. 
RNA samples harvested 100 minutes after release into fresh medium from wild type (WT), 
drug-treated (5-FU) and mutant (rrp6Δ) cells were assayed in the presence (+) or absence (-) 
of J2 antibody as shown at the top. A PCR product revealing precipitated RNA is marked to 
the right (dsRNA).  
 
S1 Fig. Global expression patterns. (A) A scatterplot matrix is shown for pair-wise 
comparisons of averaged levels calculated from duplicate samples for all annotated 
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transcripts. (B) Color coded graphs to the left plot the ratios of log2-transformed expression 
signals for mutant (rrp6) and wild type (WT) cells (left), and treated (5-FU) and untreated 
(WT)  cells (right), at the 40-minute time point (x-axis) against the tag density (y-axis). The 
legend indicates the color code for different classes of lncRNAs. Box plots to the right show 
the mutant over wild type signal ratio distributions (y-axis) for the given transcript types (x-
axis).     
 
S2 Fig. Gene Ontology (GO) term enrichment. (A-C) Enrichment data are shown as 
ReviGO plots for cluster C3, C4 and C5.  
 
S3 Fig. dsRNA formation in vivo in haploid cells. A graphical display from the online 
viewer at http://vm-gb.curie.fr/mw2/small_RNA-seq/ is given for the genes delineated by 
vertical red lines. Bar diagrams show log2 tag densities representing reads (y-axis) for 15 kb 
regions (x-axis). Genome coordinates are given at the bottom and the chromosome number is 
shown at the top. Samples from a wild type (WT) control and a genetically altered strain 
expressing Dicer and Argonaute (RNAi) are given at the top. Top (+) ad bottom (-) strands 
are indicated to the right. Transcripts are color-coded in blue (mRNAs), red (XUTs), grey 
(SUTs), green (CUTs) and black (tRNAs). Arrows indicate the transcriptional direction.  
 
S4 Fig. MTR3/CUT158 expression and dsRNA formation. (A) A heatmap is shown for the 
genomic region containing the s/a locus like in Fig. 7B. (B-C) RNA-Sequencing and RT-PCR 
data are plotted like in Fig. 7C and D. (D) dsRNA profiling data are shown like in Fig. 7E.  
 
S5 Fig. GAP1/SUT1912 expression and dsRNA formation in mitosis and meiosis. (A) A 
color-coded heatmap is shown for the genomic region containing the s/a locus. Red and blue 
represent high and low log2-transformed values, respectively. Each line shows a sample from 
cells cultured in rich medium with glucose (YPD), presporulation medium (YPA) or 
sporulation medium (SPII 1-12h) as given to the left. Each column represent the values for an 
oligonucleotide probe present on a yeast tiling array. Chromosome numbers, top (+) and 
bottom (-) strand are indicated. Horizontal black lines represent DNA strands. ORFs are 
given in blue, lncRNAs in mauve. Genome coordinates are shown. (B) dsRNA-profiling data 
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are shown for the genomic region like in S3 Fig. Blue dotted arrows represent dubious ORFs. 
(C) A J2 RIP assay for GAP1/SUT1912 is shown. Lane 1 contains molecular weight markers 
(MW). Samples from cells cultured in rich medium and sporulation medium were 
precipitated as given at the top.  
 
S6 Fig. 5-FU response of genes conserved between budding- and fission yeast. Bar 
diagrams of RNA-Sequencing data are shown for three conserved genes involved in RNA 
processing, like in Fig 7A.  
 
S1 Table. RNA-Sequencing mapping statistics.  
 
S2 Table. Cluster distribution for mRNA, lncRNAs and all transcripts. 
 
S3 Table. GO term enrichment statistics for mRNA clusters.  
 
S4 Table: Cluster distribution for sense/antisense loci 
 
 
 
 
 
 
 
 
 
 
 
Tables 
Ac
ce
pte
d M
an
us
cri
pt
 32
Table 1. Yeast strains 
Strain number  Genotype Reference and source 
MPY1 JHY222 MATa/α [16] 
MPY392 JHY222 MATa/α rrp6/rrp6 [16] 
MPY827 BY4743 MATa/α EUROSCARF 
MPY828 BY4743 MATa/α swi5/swi5 J. Horecka 
MPY830 BY4743 MATa/α ace2/ace2 EUROSCARF 
 
Table 2. Oligonucleotides for RT-PCR assays.  
Target  Forward primer Reverse primer 
ACE2 5’-TGCCCATGCGGAAAGAGATT-3’ 5’-TCGCAGCTGTTCCTCCATTT-3’ 
ACT1 5’-CTGCCGGTATTGACCAAACT-3’ 5’-AGATGGACCACTTTCGTCGT-3’ 
AMN1 5’-AAGGAGAAGAAGCAAGGGGC-3’ 5’-GCAAACCCCACAGTTTCCAC-3’ 
CUT158 5’-AGGACACCAAACATCGCTCA-3’ 5’-TTTGCTTTGCGAATCGTCGT-3’ 
MNL1 5’-GCAGGAAGTGAAGGAGCTGT-3’ 5’-TGCCATATTCTGGGCGAGAC-3’ 
MTR3 5’-GCTAGCCTTAGCTGATGCCG-3’ 5’-GCAACGATCAAGGCATTCCA-3’ 
SUT597 5’-TGTCTACTCGTCGCACTTGG-3’ 5’-GTAGCCTCTTCGTCTGGTGG-3’ 
SUT2107 5’-CTGCAATGACACCCCACAAA-3’ 5’-CCTCGTGCTTGTATGACTGC-3’ 
SWI5 5’-CGCTGGGACCACTTTCTGAT-3’ 5’-TCGCGCAACTCTTGTTGTTG-3’ 
GAP1 5’-TTGTTGCCGCCTCCAAAAAG-3’ 5’-CCCCAGTAGGAACCCCAAAC-3’ 
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